AstraZeneca announces FluMist Quadrivalent approved and available in Canada; Sinovac gets CFDA approval to start clinical trials of varicella vax;

> AstraZeneca ($AZN) Canada announced the approval and availability of FluMist Quadrivalent. Release

> Beijing-based Sinovac Dalian ($SVA) got approval from the China FDA to begin clinical trials of its varicella vaccine. Release

> Indian Immunologicals announced that its new $38 million facility to produce human and animal vaccines has begun operations. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.